KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

KALETRA CAPSULES

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

 

GENERIC NAME:

LOPINAVIR

 

MANUFACTURER:

ABBOTT LABORATORIES

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Infection, human immunodeficiency virus

 

SIDE EFFECTS:

Diabetes mellitus or hyperglycemia

pancreatitis

Diarrhea

nausea

Abdominal pain

abnormal stools

asthenia

headache

insomnia

pain

rash

vomiting

Redistribution of body fat

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Diabetes mellitus

Hemophilia A

Hemophilia B

>> Hepatic function impairment

>> Hepatitis B

>> Hepatitis C

>> Pancreatitis

 

ADULT DOSE:

Antiviral- Oral, 400 mg of lopinavir and 100 mg of ritonavir (3 capsules) two times a day with food. The dose may be increased to 533 mg of lopinavir and 133 mg of ritonavir (4 capsules) two times a day with food when used in combination with efavirenz or nevirapine in treatment-experienced patients in whom reduced susceptibility to lopinavir is suspected.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

This dosage form is usually not used in children. See Lopinavir and Ritonavir Oral Solution.  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Antiviral- Oral, 400 mg of lopinavir and 100 mg of ritonavir (3 capsules) two times a day with food. The dose may be increased to 533 mg of lopinavir and 133 mg of ritonavir (4 capsules) two times a day with food when used in combination with efavirenz or nevirapine in treatment-experienced patients in whom reduced susceptibility to lopinavir is suspected.

 

 

PREVIOUS

  

NEXT